SCHEMBL703225

SCHEMBL703225

CCOC(=O)c1cc2c(Cl)c(Cl)ccc2n1CC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MAPT P10636 7/20 0.45
KDM4E B2RXH2 6/20 0.45
TDP1 Q9NUW8 4/20 0.45
MAPK1 P28482 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
KRAS P01116 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.43
NOD2 Q9HC29 1/20 0.43
NOD1 Q9Y239 1/20 0.43
TSHR P16473 3/20 0.42
POLB P06746 2/20 0.42
ATM Q13315 1/20 0.42
F10 P00742 1/20 0.42
HSD17B10 Q99714 2/20 0.41
PPARG P37231 1/20 0.41
RAB9A P51151 1/20 0.41
NCOA2 Q15596 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19332364 0.88 KRAS (0.55) ALDH1A1MAPTKDM4EMAPK1L3MBTL1
SCHEMBL6308528 0.85 CCR2 (0.53) ALDH1A1MAPTKDM4ETDP1MAPK1
SCHEMBL700633 0.83 CCR2 (0.48) ALDH1A1MAPTKDM4ETSHRPOLB
SCHEMBL31332454 0.81 MAPT (0.45) ALDH1A1MAPTKDM4ETDP1MAPK1
SCHEMBL22760161 0.80 MEN1 (0.53) ALDH1A1MAPTKDM4ENPSR1SMN1; SMN2
SCHEMBL31416336 0.78 CACNA1B (0.39) ALDH1A1MAPTKDM4ETDP1MAPK1
SCHEMBL6596419 0.78 ABCB11 (0.57) ALDH1A1MAPTKDM4ETDP1MAPK1
SCHEMBL8689838 0.77 ALDH1A1 (0.54) ALDH1A1MAPTKDM4ETDP1MAPK1
SCHEMBL701977 0.77 KDM4E (0.52) ALDH1A1MAPTKDM4ETDP1L3MBTL1
SCHEMBL28461394 0.76 CYP4F2 (0.42) ALDH1A1MAPTKDM4ETDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124766-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2367817-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-09-28 EP disclosed
WO-2010065310-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE VIA PHARMACEUTICALS, INC (US) 2010-06-10 WO disclosed
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE MADRIGAL PHARMACEUTICALS, INC. 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT ALDH1A1 586/4885MAPT 3898/4885KDM4E 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.